fortum 500 mg prá&scaron;ek pro injekční roztok - søkeresultat

Armenia - engelsk - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

fortum

glaxosmithkline manufacturing s.p.a. - ceftazidime (ceftazidime pentahydrate) - powder for solution for injection/infusion - 1000mg

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

fortum 1g powder for injection vial

aspen pharmacare australia pty ltd - ceftazidime pentahydrate, quantity: 1.164 g (equivalent: ceftazidime, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate - fortum is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials , but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. respiratory tract infections: for example, pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections: for example, otitis media, mastoiditis. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. skin and soft tissue infections: for example, erys

fortum powder for solution for injection/infusion

glaxosmithkline manufacturing spa - ceftazidime (ceftazidime pentahydrate) - powder for solution for injection/infusion - 500mg

fortum powder for solution for injection/infusion

glaxosmithkline manufacturing s.p.a. - ceftazidime (ceftazidime pentahydrate) - powder for solution for injection/infusion - 1000mg

Den europeiske union - islandsk - EMA (European Medicines Agency)

padcev

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - Æxlishemjandi lyf - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.